Drug Profile
Research programme: immunoconjugates - BioAlta/Pfizer
Alternative Names: CAB immune checkpoint inhibitors - BioAtla/Pfizer; CAB-CTLA4Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator BioAtla; Pfizer
- Class Immunoconjugates
- Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 03 Apr 2019 Pharmacodynamic data for Cancer presented at the 110th Annual Meeting of the American Association of Cancer Research (AACR-2019)
- 01 Jan 2019 Preclinical trials in Cancer in USA (Parenteral)